$AZTR

Azitra, Inc.

Azitra is a biopharmaceutical company based in Branford, Connecticut, that develops precision dermatology treatments for skin diseases. Its product candidates use genetically modified strains of S. epidermidis. ATR-04 targets rashes associated with certain cancer therapies, while ATR-12 is intended for Netherton syndrome. ATR-01 expresses an engineered human filaggrin protein and is being developed for ichthyosis vulgaris. Azitra also works with Bayer to identify and characterize bacterial strains for topical formulations.

AlphAI earnings readQ3 FY2026 · NOV 12Azitra reports Q3 2026 net loss of $(2,949,779) against $(2,764,528) a year earlier; no revenue line is printedVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
1
1

No SEC Form 4 filings for $AZTR in the last 30 days.

See all $AZTR insider activity →
Med

Young Pharmaceuticals Signals Activist Intent at Azitra with 5.22% Stake

Young Pharmaceuticals disclosed a 5.22% stake in Azitra, holding 316,300 shares. The company plans to engage with Azitra's board to discuss ways to increase stockholder value, but has not specified any particular changes. Young Pharmaceuticals is a dermatological and aesthetic skincare company.

Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates

Azitra, Inc. (AZTR) reported Q3 2026 results, highlighting progress in ATR-COSF and ATR-04 programs. ATR-COSF showed 50% reduction in fine lines and improved skin elasticity in ex vivo studies. ATR-04 advanced to Cohort 2, expanding trial eligibility. Q3 net loss was $3.0M, with $3.8M in cash. Initial human study results for ATR-COSF and topline data for ATR-04 expected by year-end.

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. to Present Research at BIO-Europe ® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models Initial results from first-in-human study with ATR-COSF anticipated by year-end BRANFORD, Conn. – November 10, 2026 — Azitra, Inc

AZTR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning AZTR (Azitra, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.

Recent AZTR coverage spans financial news, technology and earnings.

What's driving AZTR

AlphAI scores every news story that mentions AZTR with an AI model for sentiment and relevance, and aggregates insider trades from Azitra, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AZTR

Score
$AZTRMedEarnings

Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates

Azitra, Inc. (AZTR) reported Q3 2026 results, highlighting progress in ATR-COSF and ATR-04 programs. ATR-COSF showed 50% reduction in fine lines and improved skin elasticity in ex vivo studies. ATR-04 advanced to Cohort 2, expanding trial eligibility. Q3 net loss was $3.0M, with $3.8M in cash. Initial human study results for ATR-COSF and topline data for ATR-04 expected by year-end.

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. to Present Research at BIO-Europe ® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models Initial results from first-in-human study with ATR-COSF anticipated by year-end BRANFORD, Conn. – November 10, 2026 — Azitra, Inc

$AZTRMedAI 8/10Clinical / regulatory · trial start

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

Azitra, Inc. (NYSE American: AZTR) will present research at BIO-Europe® showing ATR-COSF reduced fine lines and improved elasticity in ex vivo human skin models. Initial results from a first-in-human study are anticipated by year-end. The company also provided updates on its ATR-04 program for cancer treatment-associated rashes, expanding the trial to include additional patient groups.

$AZTRMedAI 8/10

Azitra expands trial eligibility for ATR-04 skin rash treatment

Azitra Inc. (NYSE American: AZTR) expanded its Phase 1/2 trial of ATR04-484 to include patients with rashes from KRAS/MEK inhibitors and NF1. The trial now has shorter washout periods for antibiotics and steroids. ATR04-484, a live biotherapeutic, has FDA Fast Track designation for cancer treatment-associated rash. The company aims to enroll 24 patients in Cohort 2 for a 28-day treatment period.

$AZTRMedClinical / regulatory

Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rash Add

AZTR Stock Jumps As Azitra Confirms 1-For-10 Reverse Split

Azitra Inc. (AZTR) stock surged after announcing a 1-for-10 reverse split, reducing its share count from 60.6M to 6.06M. The move aims to maintain NYSE American listing standards. AZTR reported a quarterly net loss of $3.35M with $6.7M in cash. The stock is highly volatile, trading at $1.53 after a significant intraday move.

$AZTRMedAI 8/10

Azitra reports cosmetic product reduces wrinkles in skin study

Azitra Inc. (AZTR) reported ex vivo study results showing its ATR-COSF cosmetic product reduced fine lines and wrinkles in human skin samples. A 2% formulation showed up to 50% reduction in wrinkles at 48 hours, while a 4% formulation improved elasticity. The company plans to present detailed data at BIO-Europe and expects initial human trial results by year-end. CEO Francisco Salva mentioned potential additional investments of $5.25M to $10.5M from earlier financial instruments.

$AZTRMedAI 8/10Clinical / regulatory

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin ● ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, fi

Related tickers